AI, security, digital tools, software and products, startups, semiconductors, industrial technology, and the policy around them.
Coinkite warned on July 30, 2026, that seeds created by several Coldcard models on affected firmware may be exposed because seed generation used a general-purpose pseudorandom generator. A build integration error silently routed the process away from the hardware random-number generator without stopping the firmware build.
A September 2025 paper argued that language-model training and widely used benchmarks reward guessing over acknowledging uncertainty. A 2026 health-chatbot audit found 49.6 percent of answers problematic, showing how fluent errors can reach high-stakes uses.
AI-designed drug candidates have moved into mid- and late-stage trials, but APPI News found no publicly identified US approval for a novel drug originating from an AI-led discovery program as of August 4, 2026. Early data point to faster candidate selection and stronger Phase 1 results, while later trials still impose the usual tests of safety and efficacy.
Taiwan-listed Bionime secured a local medical-device license for its iFree2 continuous glucose monitor in April 2026, but the public notice did not identify an AI forecasting feature. Abbott's Libre Assist offers such predictions in the United States, while Abbott's Taiwan product site lists an older sensor and does not advertise the feature.
Taiwan's health insurance agency said in August 2024 that it aimed to finish a cost-effectiveness review of AI diagnostic tools by the end of that year. APPI News could not find a published payment decision for the proposed CT brain-scan application as of August 3, 2026.
A 2025 laboratory study found that six wrist-worn trackers identified more than 90 percent of sleep intervals but correctly identified only 29.39 percent to 52.15 percent of wake intervals. Their movement and pulse sensors can show broad patterns, but their sleep-stage estimates do not match direct physiological measurements consistently.
The US Food and Drug Administration cleared UpDoc on December 23, 2025, as prescription software for adults with type 2 diabetes. Its chat interface collects patient data, while insulin instructions follow clinician-set treatment parameters.
Oregon enacted an AI companion law in 2026 that requires crisis protocols and allows harmed users to sue. Illinois, Nebraska, Tennessee and Maine have taken different approaches, leaving the rules dependent on a product's claims, design and users.
LayerX reported on June 29, 2026, that six agentic browsers and browser plugins copied test SSH credentials after a rigged online game changed the rules they followed. The proof of concept shows how untrusted web content can reach authenticated resources when an agent is allowed to browse and act with a user's access.
Taiwan completed government trials of three zero-trust controls between 2022 and 2024, while 47 top-tier agencies received help deploying identity checks. Financial regulators are taking a phased approach that starts with guidance and may later put implementation principles into baseline rules.
Taiwan's health ministry says three hospital groups completed a cross-system FHIR demonstration by the end of 2025. The standard can make records easier for software and AI tools to query, but it does not settle data quality, access control or accountability.
The World Health Organization and the International Telecommunication Union mapped the use of AI in traditional medicine in a 2025 technical brief. Their findings, combined with international medical-software standards, show why a product demonstration cannot establish clinical credibility.
Google and Amazon offer purpose-built AI accelerators for model training and inference alongside general-purpose GPUs. Custom chips can improve efficiency on stable, heavily used workloads, but development cost, software and design risk limit where they pay off.
A coalition of US state attorneys general reportedly opened an investigation into OpenAI on June 12, 2026, seeking records on advertising, data practices and vulnerable users. The subpoena arrived four days after OpenAI disclosed a confidential draft S-1, but neither the filing nor the subpoena is public.
US regulators updated two software policies in January 2026, clarifying when low-risk wellness products and some clinical decision-support functions fall outside full device oversight. Taiwan requires qualifying AI medical software to enter its device-registration system, while the European Union layers high-risk AI obligations onto existing product rules.
GPT-5 Pro generated a mechanism for unexplained T-cell data and predicted the direction of an unpublished CAR-T experiment, according to a November 2025 case study. The result shows how a model can help experts form testable hypotheses, but it does not establish autonomous discovery or prove the proposed mechanism.
OpenAI and Molecule.one reported on June 17 that a GPT-5.4 workflow helped identify conditions that improved a difficult Chan-Lam coupling across 10,080 microscale reactions. An automated laboratory supplied the testing capacity, while chemists selected proposals, corrected plans and repeated key experiments by hand.
OpenAI reported in June 2026 that GPT-Rosalind passed 36.1 percent of the 750 tasks in its new LifeSciBench evaluation. Performance fell on tasks involving figures, files or web sources, while the benchmark's design and publication by OpenAI complicate interpretation of its model rankings.
